Simplification From Protease Inhibitors to Raltegravir
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
A switch from protease inhibitors (PIs) to raltegravir (RAL) will be effective virologically
and immunologically. Moreover, it will be associated with significant improvements in the
lipid profile in HIV patients with undetectable viremia on PIs. In this setting, RAL once a
day (QD) will perform as well as RAL twice a day (BID).
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Carlos III, Madrid
Treatments:
HIV Protease Inhibitors Protease Inhibitors Raltegravir Potassium